Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Photocure ASA (OSE: PHO) has scheduled publication of its fourth-quarter and preliminary full-year 2025 financial results for 18 February 2026 at 08:00 CET, with the quarterly report and presentation to be published at 07:00 CET and a live investor webcast at 14:00 CET hosted by CEO Dan Schneider and CFO Erik Dahl. The announcement is a routine earnings timetable notice (no financial figures included) and signals an upcoming material disclosure for investors in the bladder-cancer diagnostics specialist; stakeholders should review the report on release for any surprises to revenue, margins or guidance that could move the stock. Contact and webcast details are provided for investor Q&A and media inquiries.

Analysis

Market structure: Photocure (PHO:OSE) is an event-driven micro-/small-cap where a clean Q4 and FY2025 preview can meaningfully reprice revenue multiples given concentrated commercial exposure to Cysview in the U.S. Winners: PHO (market share in blue-light cystoscopy), urology centers with higher procedure throughput, and specialty distribution partners if uptake accelerates >25% y/y. Losers: low-cost white-light cystoscopy competitors and over-levered small-cap biotechs as capital flows rotate to predictable commercial revenues.

Risk assessment: Immediate tail risks are a surprise revenue/guidance miss, negative commentary on U.S. reimbursement or supply interruptions; low-probability regulatory actions (FDA safety signal) could erase >70% equity value. Time horizons: expect 1–5 day volatility around Feb 18, directional re-rating over 3–12 months based on U.S. adoption curves; hidden dependency: reimbursement codes/CPT and hospital budget cycles drive quarter-to-quarter lumpiness.

Trade implications: If previews show organic U.S. growth >25% y/y and EBITDA inflection, establish a small tactical long (1–3% NAV) in PHO; if guidance disappoints, use puts or short via CFDs. Options play: buy 1–3 month ATM calls if implied vol <45% ahead of the webcast, otherwise use call spreads to cap premium. Pair trade: long PHO vs short IBB to isolate commercial execution risk; target 6–12 month holding period.

Contrarian angles: Consensus may underweight conversion lag (training & OR scheduling) — a modest upside beat can produce outsized re-rating if the company proves repeatable monthly sales. Conversely, the market may be too patient: failure to show steady U.S. roll-out cadence within 2–3 quarters should materially de-rate multiple; history shows Photocure-like commercial rollouts are lumpy before scaling.

Key Decisions for Investors

• Establish a 1–3% NAV long position in Photocure (PHO:OSE) ahead of the Feb 18 webcast if preliminary materials show U.S. sales growth >25% y/y and positive EBITDA trajectory; set stop-loss at -20% and take-profit tranche at +50% within 6–12 months.
• If PHO provides weak guidance or U.S. uptake misses (U.S. q/q growth <5% or FY2026 guidance growth <15%), initiate a short via European CFD or buy 3-month puts sized 0.5–1% NAV, target -40% downside, reassess after 90 days.
• Implement a relative-value trade: long PHO (1% NAV) and short IBB (0.5% NAV) for 6–12 months to isolate idiosyncratic execution; close if PHO outperforms IBB by >30% or underperforms by >20%.
• Use options tactical: buy 1–3 month ATM calls on PHO if implied vol <45% (size 0.5–1% NAV) or buy a 2:1 call spread to cap cost if IV >45%; enter 3–7 days before Feb 18 and close within 10 trading days post-webcast unless fundamental beat justifies hold.
• Monitor three specific catalysts for the next 60–180 days before scaling: (1) U.S. monthly sales run-rate (threshold: consistent q/q growth >10%), (2) any CPT/reimbursement announcements, and (3) commentary on supply chain or partnership/licensing news — add to long if 2 of 3 are positive.